Publikationen

Gynäkologie / Gynäkologische Onkologie

  • Urech C, Ehrbar V, Boivin J, Muller M, Alder J, Zanetti Dallenbach R, Rochlitz C, Tschudin S: Knowledge about and attitude towards fertility preservation in young female cancer patients: a cross-sectional online survey. Hum Fertil (Camb) 2018, 21:45-51.
  • Ehrbar V, Urech C, Rochlitz C, Dallenbach RZ, Moffat R, Stiller R, Fah M, von Wolff M, Nawroth F, Dangel A, Germeyer A, Findeklee S, Tschudin S: Fertility Preservation in Young Female Cancer Patients: Development and Pilot Testing of an Online Decision Aid. J Adolesc Young Adult Oncol 2018, 7:30-6.
  • Muller M, Urech C, Boivin J, Ehrbar V, Moffat R, Daellenbach RZ, Rochlitz C, Tschudin S: Addressing decisional conflict about fertility preservation: helping young female cancer survivors' family planning decisions. BMJ Sex Reprod Health 2018, 44:175-80.
  • Zanetti Dällenbach R.: Brustschmerz führt oft zu Verunsicherung. Praxis (Bern 1994) (2017); 106(20): 1087
  • Vetter M., Fokas S., Biskup E., Schmid T., Schwab F., Schoetzau A., Güth U., Rochlitz C., Zanetti Dällenbach R.: Efficacy of Adjuvant Chemotherapy with Carboplatin for Early Triple Negative Breast Cancer: A Single Center Experience. Oncotarget. 2017 May 23; 8(43): 75617-26.
  • Elastography Complements Ultrasound as Principle Modality in Breast Lesion Assessment. Redling, K., F. Schwab, M. Siebert, A. Schotzau and R. Zanetti-Dallenbach. Gynecol Obstet Invest 2016
  • Clinical Data as an adjunct to ultrasound reduces the false-neative malignancy rate in BI-RADS 3 breast lesions. Ackermann S., Schoenenberger C.A., Zanetti-Dallenbach R. Ultrasound International Open 2016
  • Schwab F, Redling K, Siebert M, Schotzau A, Schoenenberger CA, Zanetti-Dallenbach R: Inter- and Intra-Observer Agreement in Ultrasound BI-RADS Classification and Real-Time Elastography Tsukuba Score Assessment of Breast Lesions. Ultrasound Med Biol 2016, 42:2622-9.
  • Ehrbar V, Urech C, Alder J, Harringer K, Zanetti Dallenbach R, Rochlitz C, Tschudin S: Decision-making about fertility preservation-qualitative data on young cancer patients' attitudes and needs. Arch Womens Ment Health 2016, 19:695-9.
  • Expression of programmed death ligang 1 (PD-L1) is associated with poor prognosis  in human breast cancer. Muenst S, Schaerli AR, Gao F, Däster S, Trella E, Droeser RA, Murarao MG, Zajac P, Zanetti R, Gillanders WE, Weber WP, Soysal SD. Breast Cancer Res. Treat. 2014 Jul;146(1):15-24
  • The nanomechanical signature of breast cancer. Plodinec M, Lopric M, Monnier CA, Obermann EC, Zanetti-Dällenbach R (shared 2nd author), Oertle P,  Hyotyla JT, Aebi U, . Bentires-Alj M,  Lim RY, Schoenenberger CA. Nat Nanotechnol. 2012 Nov. 7(11):757-65
  • Das Zervixkarzinom – Was die Hausärztin darüber wissen muss. Zanetti-Dällenbach R.Hausarzt Praxis 2012 / 12-13
  • Viehl CT, Langer I, Guller U, Zanetti-Dallenbach R, Moch H, Wight E, Oertli D, Zuber M: Prognostic impact and therapeutic implications of sentinel lymph node micro-metastases in early-stage breast cancer patients. J Surg Oncol 2011, 103:531-3.
  • IGF-I induced genes in stromal fibroblasts predict the clinical outcome of breast and lung cancer patients. Rajski M, Zanetti-Dallenbach R, Vogel B, Herrmann R, Rochlitz C, Buess M. BMC Med. 2010 Jan 5; 8:1
  • Impact of hormone replacement therapy on the histologic subtype of breast cancer. Zanetti-Dällenbach RA, Krause EM, Lapaire O, Gueth U, Holzgreve W, Wight E. Arch Gynecol Obstet. 2008 Nov;278(5):443-9 
  • Accuracy of frozen section analysis versus specimen radiography during breast-conserving surgery for nonpalpable lesions. Weber WP, Engelberger S, Viehl CT, Zanetti-Dallenbach R, Kuster S, Dirnhofer S, Wruk D, Oertli D, Marti WR. World J Surg. 2008 Dec;32(12):2599-606 
  • Target and reality of adjuvant endocrine therapy in postmenopausal patients with invasive breast cancer. Güth U, Huang DJ, Schötzau A, Zanetti-Dällenbach R, Holzgreve W, Bitzer J, Wight E. Br J Cancer. 2008 Aug 5;99(3):428-33 
  • Tumor size and detection in breast cancer: Self-examination and clinical breast examination are at their limit. Güth U, Huang DJ, Huber M, Schötzau A, Wruk D, Holzgreve W, Wight E, Zanetti-Dällenbach R. Cancer Detect Prev. 2008;32(3):224-8 
  • Sexual dysfunction after premenopausal stage I and II breast cancer: do androgens play a role? Alder J, Zanetti R, Wight E, Urech C, Fink N, Bitzer J. J Sex Med. 2008 Aug;5(8):1898-906 
  • Positive correlation of cell-free DNA in plasma/serum in patients with malignant and benign breast disease. Zanetti-Dällenbach R, Wight E, Fan AX, Lapaire O, Hahn S, Holzgreve W, Zhong XY. Anticancer Res. 2008 Mar-Apr;28(2A):921-5
  • Mamma- und gynäkologische Karzinome in der Schwangerschaft. Zanetti-Dällenbach R., Güth U., Lapaire O. up2date 2008;2:489-506
  • Smoking during pregnancy (Rauchen in der Schwangerschaft). Hösli I, Zanetti-Dallenbach R, Holzgreve W, Lapaire O. Frauenheilkunde; 68:141-146;2008
  • Pregnancy-associated breast cancer. Eisenbrand MC, Wight E, Güth U, Zanetti-Dällenbach R.Ther Umschl. 65(4) 223-9; Apr 2008
  • Levels of circulating cell-free serum DNA in benign and malignant breast lesions. Zanetti-Dällenbach RA, Schmid S, Wight E, Holzgreve W, Ladewing A, Hahn S, Zhong XY. Int J Biol Markers. 2007 Apr-Jun;22(2):95-9
  • Breast Edema mimicking Inflammatory Breast Cancer (Differenzialdiagnose inflammatorisches Mammakarzinom: brustödem nach Thrombose der V.Brachiocephalica). 
  • Psychological management of pregnancy-related breast cancer. Zanetti-Dällenbach R, Tschudin S, Lapaire O, Holzgreve W, Wight E, Bitzer J. Breast. 2006 Dec;15 Suppl 2:S53-9. Review. Erratum in: Breast. 2008 Apr;17(2):213 
  • Comparison of gene expression profiles in core biopsies and corresponding surgical breast cancer samples. Zanetti-Dällenbach R, Vuaroqueaux V, Wight E, Labuhn M, Singer G, Urban P, Eppenberger U, Holzgreve W, Eppenberger-Castori S. Breast Cancer Res. 2006;8(4):R51
  • Mammotome: less invasive than ABBI with similar accuracy for early breast cancer detection. Weber WP, Zanetti R, Langer I, Dellas S, Zuber M, Moch H, Remmel E, Oertli D, Wight E, Marti WR. World J Surg. 2005 Apr;29(4):495-9
  • Zanetti-Dallenbach R, Wight E: [Chemotherapy for gynecological malignancies--a contraindication during pregnancy?]. Ther Umsch 2005, 62:53-60.
  • Dallenbach RZ, De Geyter M, Holzgreve W: Desire for children in tumor patients. Ther Umsch 1999, 56:276-81.

Onkologie

  • Tibau A, Anguera G, Andrés-Petrel F, Templeton AJ, Seruga B, Barnadas A, Amir E, Ocana A. Role of cooperative groups and funding source in clinical trials supporting guidelines for systemic therapy of breast cancer. Oncotarget 2018 [in press] IF 5.168 (JCI 2016; rank x/217 oncology)
  • Templeton AJ, Rodríguez Lescure A, Ruíz A, Alba E, Calvo L, Ruíz Borrego M, Santaballa A, Rodríguez CA, Crespo C, Ramos M, Gracia Marco J, Lluch A, Álvarez I, Casas M; Sánchez-Aragó M; Caballero R; Carrasco E, Amir E, Martin M, Ocaña A. Prognostic role for the derived neutrophil-to-lymphocyte ratio in early breast cancer: a GEICAM/9906 substudy. Clinical and Translational Oncology 2018 [in press] IF 2.353 (JCI 2016; rank 142/217 oncology)
  • Baumann M, Dani SU, Dietrich D, Hochstrasser A, Klingbiel D, Mark MT, Riesen WF, Ruhstaller T, Templeton AJ, Thürlimann B. Vitamin D levels in Swiss breast cancer survivors. Swiss Med Wkly 2017 [in press] IF 1.654 (JCI 2016; rank 68/155 medicine, general & internal)
  • Goldvaser H, AlGorashi I, Ribnikar D, Seruga B, Templeton AJ, Ocana A, Amir E. Efficacy of Extended Adjuvant Therapy with Aromatase Inhibitors in Early Breast Cancer among Common Clinicopathologically-defined Subgroups: A Systematic Review and Meta-analysis. Cancer Treat Rev. 2017 Sep;59:46-53. doi: 10.1016/j.ctrv.2017.06.007. IF 7.122 (JCI 2016; rank 16/217 oncology)
  • Gonzalez-Conchas GA, Rodriguez-Romo L, Hernandez Barajas D, Gonzalez-Guerrero JF, Rodriguez-Fernandez IA, Verdines-Perez A, Templeton AJ, Ocana A, Seruga B, Tannock IF, Amir E, Vera-Badillo FE.  Epidermal Growth Factor Receptor overexpression and outcomes in early breast cancer: A systematic review and a meta-analysis. Cancer Treat Rev. 2017 Oct 31;62:1-8. doi: 10.1016/j.ctrv.2017.10.008. IF 8.589 (JCI 2016; rank 16/217 oncology)
  • Goldvaser H, Ribnikar D, Fazelzad R, Seruga B, Templeton AJ, Ocana A, Amir E. Influence of Non-Measurable Disease on Progression-Free Survival in Patients with Metastatic Breast Cancer. Cancer Treat Rev. 2017 Sep;59:46-53. doi: 10.1016/j.ctrv.2017.06.007. IF 7.122 (JCI 2016; rank 16/217 oncology)
  • Ethier J-L, Desautels D, Templeton AJ, Shah P, Amir E. Prognostic Role of Neutrophil-to Lymphocyte Ratio in Breast Cancer: A Systematic Review and Meta-Analysis. Breast Cancer Res. 2017 Jan 5;19(1):2. doi: 10.1186/s13058-016-0794-1. IF 3.626 (JCI 2016; rank 82/217 oncology)
  • Templeton AJ, Diez Gonzalez L, Vera-Badillo FE, Tibau A, Goldstein R, Šeruga B, Srikanthan A, Pandiella A, Amir E, Ocana A Interaction between hormonal receptor status, age and survival in patients with BRCA1/2 germline mutations: A systematic review and meta-regression. PLoS One. 2016 May 5;11(5):e0154789. doi: 10.1371/journal.pone.0154789. eCollection 2016. IF 2.806 (JCI 2016; rank 15/64 multidisciplinary sciences)
  • Ocaña A, Pérez-Peña J, Díez-González L, Sánchez-Corrales V, Templeton A, Seruga B, Amir E, Pandiella A. Transcriptomic analyses identify association between mitotic kinases, PDZ binding kinase and BUB1, and clinical outcome in breast cancer. Breast Cancer Res Treat. 2016 Feb;156(1):1-8. doi: 10.1007/s10549-016-3720-4. IF 3.626 (JCI 2016; rank 82/217 oncology)
  • Wolfgang Harms, Andreas Geretschläger, Corinne Cescato, Martin Buess,Dieter Köberle, Branca Asadpour, “Current Treatment of Isolated Locoregional Breast Cancer Recurrences”, 2015,  Breast Care;10:265–271
  • Harms W, Geretschläger A, Cescato C, Buess M, Köberle D, Asadpour B.. Current Treatment of Isolated Locoregional Breast Cancer Recurrences. Breast Care (Basel). 2015 Aug;10(4):265-71
  • Vera-Badillo FE, Chang MC, Kuruzar G, Ocana A, Templeton AJ, Seruga B, Goldstein R, Bedard PL, Tannock IF, Amir E. Association between Androgen Receptor Expression, Ki-67 and the 21 Gene Recurrence Score in Non-metastatic, Lymph node-negative, Estrogen Receptor-positive and HER2-negative Breast Cancer. J Clin Pathol. 2015 Jun 15. pii: jclinpath-2015-203012. doi: 10.1136/jclinpath-2015-203012. IF 2.687 (JCI 2016; rank 22/79 pathology)
  • Templeton AJ, Ace O, Amir E, Vera-Badillo F, Ocana A, Pond GR, Tannock IF. Influence of censoring on conclusions of trials for women with metastatic breast cancer. Eur J Cancer. 2015 Apr;51(6):721-4. doi: 10.1016/j.ejca.2014.12.016. (Current Perspective) IF 6.029 (JCI 2016; rank 34/217 oncology)
  • Templeton AJ, Diez Gonzalez L, Ace O, Vera-Badillo F, Šeruga B, Jordán J, Amir E, Pandiella A, Ocaña A. Prognostic Relevance of Receptor Tyrosine Kinase Expression in Breast Cancer: A meta-analysis. Cancer Treat Rev. 2014 Oct;40(9):1048-55. doi: 10.1016/j.ctrv.2014.08.003.  IF 7.983 (JCI 2015; rank 14/213 oncology)
  • Vera-Badillo FE, Napoleone M, Ocana A, Templeton AJ, Al-Mubarak M, Tannock IF, Amir E. Effect of Multifocality and Multicentricity on Outcome in Early Stage Breast Cancer: A Systematic Review and Meta-Analysis. Breast Cancer Res Treat. 2014 Jul;146(2):235-44. doi: 10.1007/s10549-014-3018-3. IF 4.085 (JCI 2015; rank 57/213 oncology)
  • Templeton AJ, Ribi K, Surber C, Sun H, Hsu Schmitz S-F, Beyeler M, Dietrich D, Borner M, Winkler A, Müller A, von Rohr L, Winterhalder RC, Rochlitz C, von Moos R, Zaman K, Thürlimann BJK, Ruhstaller T. Prevention of palmar-plantar erythrodysesthesia with an antiperspirant in breast cancer patients treated with pegylated liposomal doxorubicin (SAKK 92/08). Breast. 2014 Jun;23(3):244-9. doi: 10.1016/j.breast.2014.02.005 IF 2.740 (JCI 2015; rank 116/213 oncology)
  • Al-Mubarak M, Tibau A, Templeton AJ, Cescon DW, Ocana A, Seruga B, Amir E. Extended Adjuvant Tamoxifen for Early Breast Cancer: A Meta-analysis. PLoS One. 2014 Feb 20; (2):e88238. doi: 10.1371/journal.pone.0088238. IF 3.057 (JCI 2015; rank 11/63 multidisciplinary sciences)
  • Vera-Badillo F, Templeton AJ, de Gouveia P, Diaz-Padilla I, Bedard P, Al-Mubarak M, Seruga B, Tannock I,  Ocana A, Amir A. Androgen Receptor Expression and Outcomes in Early Breast Cancer: A Systematic Review and Meta-Analysis. J Natl Cancer Inst. 2014 Jan;106(1):djt319. doi: 10.1093/jnci/djt319. IF 11.370 (JCI 2015; rank 9/213 oncology)
  • Templeton AJ, Thürlimann B, Baumann M, Mark M, Stoll S, Schwizer M, Dietrich D, Ruhstaller T. Cross-Sectional Study of Self-Reported Physical Activity, Eating Habits and Use of Complementary Medicine in Breast Cancer Survivors. BMC Cancer. 2013 Mar 25;13:153. doi: 10.1186/1471-2407-13-153. IF 3.362 (JCI 2014; rank 81/211 oncology)
  • Templeton AJ, Ocaña A, Šeruga B, Vera-Badillo F, Carlsson L, Bedard P, Amir E. Management of small HER2 overexpressing tumours. Breast Cancer Res Treat. 2012 Nov;136(1):289-93. doi: 10.1007/s10549-012-2236-9. IF 4.198 (JCI 2013; rank 49/203 oncology)
  • Rajski M, Vogel B, Baty F, Rochlitz C, Buess M., “Global Gene Expression Analysis of the Interaction between Cancer Cells and Osteoblasts to predict Bone Metastasis in Breast Cancer”, 2012, PLoS One 7(1):e29743. Epub 2012 Jan 3
  • Huober J, Spirig C, Schoch O, Templeton A, Thürlimann B. Interstitial Pneumonitis after Treatment with Bevacizumab and Pegylated Liposomal Doxorubicin in a Patient with Metastatic Breast Cancer.  Chemotherapy. 2010;56(1):69-70. doi: 10.1159/000282286. (Letter / Case report) IF 1.816 (JCI 2011; rank 132/196 oncology, 153/261 pharmacology & pharmacy)
  • Rajski M, Zanetti-Dallenbach R, Vogel B, Herrmann R, Rochlitz C, Buess M., “IGF-I induced genes in stromal fibroblasts predict the clinical outcome of breast and lung cancer patients”, 2010 BMC Medicine Jan 5;8 (1):1
  • Martin Buess, Michal Rajski, Brigitte ML Vogel-Durrer, Richard Herrmann and Christoph Rochlitz, “Tumor-Endothelial Interaction links the CD44+/CD24− Phenotype with Poor Prognosis in Early-Stage Breast Cancer”, 2009 Neoplasia 11(10), 987-1002
  • Templeton A, Thürlimann B, Jörger M. Ixabepilon bei lokal fortgeschrittenem oder metastasiertem Mammakarzinom: Neue Behandlungsoptionen nach Taxanen und Anthrazyklinen. Schweizer Krebsbulletin 2009; 2: 114 - 117 (Review)
  • Martin Buess, Dimitry S.A. Nuyten, Trevor Hastie, Torsten Nielsen, Robert Pesich and Patrick O. Brown, “Characterization of heterotypic interaction effects in vitro to deconvolute global gene expression profiles in cancer” , 2007, Genome Biology, 8 (9) R191
  • Thuerlimann B, Koeberle D*, Senn HJ (2007): Guidelines for the Adjuvant Treatment of Postmenopausal Women With Endocrine-Responsive Breast Cancer: Past, Present, and Future Recommendations. Eur J Cancer 43(1): 46-52.* korrespondierender Autor
  • Koeberle D, Thuerlimann B. (2007): Letrozole as upfront endocrine therapy for postmenopausal women with hormone-sensitive breast cancer: BIG 1-98. Breast Cancer Res Treat 105: 55–66
  • Koeberle D, Thuerlimann B (2006): Letrozole as adjuvant endocrine therapy in postmenopausal women with breast cancer. Expert Rev Anticancer Ther. 6(1): 5-10.
  • Koberle D, Thurlimann B (2005): Adjuvant endocrine therapy in postmenopausal breast cancer. Breast. 14(6): 446-5
  • Koberle D, Thuerlimann B: Anastrozole (2001): Pharmacological and clinical profile in postmenopausal women with breast cancer. Expert Rev. Anticancer Ther. 1(2): 169-176
  • Hitz F, Ribi K, Li Q, Klingbiel D, Cerny T, Koeberle D. (2013) Predictors of satisfaction with treatment decision, decision-making preferences, and main treatment goals in patients with advanced cancer. Support Care Cancer. 21(11):3085-93
  • Blum D, Koeberle D, Ribi K, Schmitz SF, Utiger U, Klingbiel D, Strasser F. (2012) Electronic monitoring of symptoms and syndromes associated with cancer: methods of a randomized controlled trial SAKK 95/06 E-MOSAIC. BMC Palliat Care 24;11:19
  • Joerger M, Templeton A, Köberle D, Engler H, Riesen WF, Thürlimann B. Procollagen type I N propeptide is a predictor of skeletal morbidity in patients with malignant osteolytic bone disease on bisphosphonates. Cancer Chemother Pharmacol. 67(5):1137-44
  • Koeberle D, Ruhstaller T, Jost L, Pagani O, Zaman K, von Moos R, Oehlschlegel C, Crowe S, Pilop C, Thuerlimann B (2011)  Swiss Group for Clinical Cancer Research (SAKK). Combination of trastuzumab and letrozole after resistance to sequential trastuzumab and aromatase inhibitor monotherapies in patients with estrogen receptor-positive, HER-2-positive advanced breast cancer: a proof-of-concept trial (SAKK 23/03). Endocr Relat Cancer 9;1 (2):257-64
  • Ruhstaller, T, von Moos R, Rufibach K, Ribi K, Glaus A, Spaeti B, Koeberle D, Mueller U, Hoefliger M, Hess D, Boehme C, Thuerlimann B (2009): Breast   cancer patients on endocrine therapy reveal more symptoms when self-reporting than in pivotal trials: an outcome research study. Oncology 76:142-148
  • Hess D, Koberle D, Thurlimann B, Pagani O, Schoenenberger A, Mattman S, Rochliz C, Rauch D, Schuller J, Ballabeni P, Ribi K (2007): Capecitabine and vinorelbine in elderly patients with metastatic breast cancer: a phase II trial. Oncology 73 (3-4): 228-237
  • Seeholzer N, Thuerlimann B, Koeberle D, Hess D, Korte W (2007): Combining chemotherapy and low-molecular-weight heparin for the treatment of advanced breast cancer: results on clinical response, transforming growth factor-beta 1 and fibrin monomer in a phase II study. Blood Coagulation and Fibrinolysis 18:415–423
  • Klaeser B, Wiederkehr O, Koeberle D, Mueller A, Bubeck B, Thuerlimann B (2007). Therapeutic impact of 2-[fluorine-18]fluoro-2-deoxy-D-glucose positron emission tomography in the pre- and postoperative staging of patients with clinically intermediate or high-risk breast cancer. Ann Oncol. 18(8): 1329-34.
  • Perey L, Paridaens R, Hawle H, Koeberle D, et al (2007): Clinical benefit of Fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II SAKK trial 21/00. Ann Oncol  18 (1): 94-96
  • Thuerlimann, D. Hess, D. Koeberle et al (2004): Anastrozole versus tamoxifen  as first-line therapy in postmenopausal women with advanced  breast cancer:  results of the double-blind cross-over SAKK trial 21/95 – a sub- study of the TARGET trial. Breast Cancer Res Treat. 85(3): 247-54

Radioonkologie

  • Krug D, Baumann R, Budach W, Dunst J, Feyer P, Fietkau R, Haase W, Harms W, Hehr T, Piroth MD, Sedlmayer F, Souchon R, Wenz F, Sauer R; Breast Cancer Expert  Panel of the German Society of Radiation Oncology (DEGRO). Neoadjuvant chemotherapy for breast cancer-background for the indication of locoregional treatment. Strahlenther Onkol. 2018 Jul 4. doi: 10.1007/s00066-018-1329-8. [Epub  ahead of print] Review. PubMed PMID: 29974132.
  • Krug D, Baumann R, Budach W, Dunst J, Feyer P, Fietkau R, Haase W, Harms W, Hehr T, Piroth MD, Sedlmayer F, Souchon R, Wenz F, Sauer R. Individualization of  post-mastectomy radiotherapy and regional nodal irradiation based on Treatment response after neoadjuvant chemotherapy for breast cancer : A systematic review.  Strahlenther Onkol. 2018 Jul;194(7):607-618. doi: 10.1007/s00066-018-1270-x. Epub 2018 Jan 30. PubMed PMID: 29383405.
  • Krug D, Baumann R, Budach W, Dunst J, Feyer P, Fietkau R, Haase W, Harms W, Piroth MD, Sautter-Bihl ML, Sedlmayer F, Souchon R, Wenz F, Sauer R; Breast cancer expert panel of the German Society of Radiation Oncology (DEGRO). Current  controversies in radiotherapy for breast cancer. Radiat Oncol. 2017 Jan 23;12(1):25. doi: 10.1186/s13014-017-0766-3. Review. PubMed PMID: 28114948; PubMed Central PMCID: PMC5259946.
  • Harms W, Budach W, Dunst J, Feyer P, Fietkau R, Haase W, Krug D, Piroth MD, Sautter-Bihl ML, Sedlmayer F, Souchon R, Wenz F, Sauer R; Breast Cancer Expert Panel of the German Society of Radiation Oncology (DEGRO). DEGRO practical guidelines for radiotherapy of breast cancer VI: therapy of locoregional breast cancer recurrences. Strahlenther Onkol. 2016 Apr;192(4):199-208. doi: 10.1007/s00066-015-0939-7. Epub 2016 Mar 1. PubMed PMID: 26931319; PubMed Central PMCID: PMC4833793.
  • Harms W, Geretschläger A, Cescato C, Buess M, Köberle D, Asadpour B. Current Treatment of Isolated Locoregional Breast Cancer Recurrences. Breast Care (Basel). 2015 Aug;10(4):265-71. doi: 10.1159/000439151. Epub 2015 Aug 21. Review. PubMed PMID: 26600763; PubMed Central PMCID: PMC4608638.
  • Budach W, Matuschek C, Bölke E, Dunst J, Feyer P, Fietkau R, Haase W, Harms W, Piroth MD, Sautter-Bihl ML, Sedlmayer F, Souchon R, Wenz F, Sauer R; Breast Cancer Expert Panel of German Society of Radiation Oncology (DEGRO). Erratum to:  DEGRO practical guidelines for radiotherapy of breast cancer V: Therapy for locally advanced and inflammatory breast cancer, as well as local therapy in cases with synchronous distant metastases. Strahlenther Onkol. 2015 Aug;191(8):634. doi: 10.1007/s00066-015-0863-x. PubMed PMID: 26087910; PubMed Central PMCID: PMC4714040.
  • Budach W, Matuschek C, Bölke E, Dunst J, Feyer P, Fietkau R, Haase W, Harms W, Piroth MD, Sautter-Bihl ML, Sedlmayer F, Souchon R, Wenz F, Sauer R; Breast Cancer Expert Panel of German Society of Radiation Oncology (DEGRO). DEGRO practical guidelines for radiotherapy of breast cancer V: Therapy for locally advanced and inflammatory breast cancer, as well as local therapy in cases with synchronous distant metastases. Strahlenther Onkol. 2015 Aug;191(8):623-33. doi:  10.1007/s00066-015-0843-1. Epub 2015 May 12. Erratum in: Strahlenther Onkol. 2015
    Aug;191(8):634. Wenz, Frederick [corrected to Wenz, Frederik]. PubMed PMID:
    25963557; PubMed Central PMCID: PMC4516860.
  • Sautter-Bihl ML, Sedlmayer F, Budach W, Dunst J, Feyer P, Fietkau R, Haase W, Harms W, Piroth MD, Souchon R, Wenz F, Sauer R; Breast Cancer Expert Panel of the German Society of Radiation Oncology (DEGRO). How nescience may obscure evidence. Strahlenther Onkol. 2014 Oct;190(10):861-3. doi: 10.1007/s00066-014-0755-5. PubMed PMID: 25238991.
  • Wenz F, Sperk E, Budach W, Dunst J, Feyer P, Fietkau R, Haase W, Harms W, Piroth MD, Sautter Bihl ML, Sedlmayer F, Souchon R, Fussl C, Sauer R; Breast Cancer Expert Panel of the German Society of Radiation Oncology (DEGRO). DEGRO practical guidelines for radiotherapy of breast cancer IV: radiotherapy following mastectomy for invasive breast cancer. Strahlenther Onkol. 2014
    Aug;190(8):705-14. doi: 10.1007/s00066-014-0687-0. PubMed PMID: 24888511.
  • Sautter-Bihl ML, Sedlmayer F, Budach W, Dunst J, Feyer P, Fietkau R, Fussl C, Haase W, Harms W, Piroth MD, Souchon R, Wenz F, Sauer R; Breast Cancer Expert Panel of the German Society of Radiation Oncology (DEGRO). DEGRO practical guidelines: radiotherapy of breast cancer III--radiotherapy of the lymphatic pathways. Strahlenther Onkol. 2014 Apr;190(4):342-51. doi: 10.1007/s00066-013-0543-7. Epub 2014 Mar 5. PubMed PMID: 24638236.
  • Souchon R, Sautter-Bihl ML, Sedlmayer F, Budach W, Dunst J, Feyer P, Fietkau  R, Haase W, Harms W, Wenz F, Sauer R; Breast Cancer Expert Panel of the German Society of Radiation Oncology (DEGRO). DEGRO practical guidelines: radiotherapy of breast cancer II: radiotherapy of non-invasive neoplasia of the breast. Strahlenther Onkol. 2014 Jan;190(1):8-16. doi: 10.1007/s00066-013 0502-3. PubMed  PMID: 24306068.
  • Harms W. Prognosis of pregnant women with primary breast cancer. Strahlenther Onkol. 2013 Nov;189(11):980-1. doi: 10.1007/s00066-013-0455-6. German. PubMed PMID: 24158605.
  • Sedlmayer F, Sautter-Bihl ML, Budach W, Dunst J, Fastner G, Feyer P, Fietkau  R, Haase W, Harms W, Souchon R, Wenz F, Sauer R; Breast Cancer Expert Panel of the German Society of Radiation Oncology (DEGRO). DEGRO practical guidelines: radiotherapy of breast cancer I: radiotherapy following breast conserving therapy for invasive breast cancer. Strahlenther Onkol. 2013 Oct;189(10):825-33. doi: 10.1007/s00066-013-0437-8. PubMed PMID: 24002382; PubMed Central PMCID: PMC3825416.
  • Sedlmayer F, Sautter-Bihl ML, Budach W, Dunst J, Feyer P, Fietkau R, Haase W, Harms W, Rödel C, Souchon R, Wenz F, Sauer R; Breast Cancer Expert Panel of the German Society of Radiation Oncology (DEGRO). Is the simultaneously integrated boost (SIB) technique for early breast cancer ready to be adopted for Routine adjuvant radiotherapy? Statement of the German and the Austrian Societies of Radiooncology (DEGRO/ÖGRO). Strahlenther Onkol. 2013 Mar;189(3):193-6. doi:
    10.1007/s00066-012-0300-3. Erratum in: Strahlenther Onkol. 2013 May;193(5):436. PubMed PMID: 23358687.
  • Sautter-Bihl ML, Sedlmayer F, Budach W, Dunst J, Feyer P, Fietkau R, Haase W, Harms W, Rödel C, Souchon R, Wenz F, Sauer R. When are breast cancer patients old enough for the quitclaim of local control? Strahlenther Onkol. 2012 Dec;188(12):1069-73. doi: 10.1007/s00066-012-0253-6. Epub 2012 Oct 28. Review. PubMed PMID: 23104521.
  • Sautter-Bihl ML, Sedlmayer F, Budach W, Dunst J, Feyer P, Fietkau R, Haase W, Harms W, Rödel C, Souchon R, Wenz F, Sauer R. One life saved by four prevented recurrences? Update of the Early Breast Cancer Trialists confirms: postoperative  radiotherapy improves survival after breast conserving surgery. Strahlenther Onkol. 2012 Jun;188(6):461-3. doi: 10.1007/s00066-012-0092-5. PubMed PMID: 22441440.
  • Sautter-Bihl ML, Sedlmayer F, Budach W, Dunst J, Engenhart-Cabillic R, Fietkau R, Feyer P, Haase W, Harms W, Rödel C, Souchon R, Wenz F, Sauer R. Intraoperative radiotherapy as accelerated partial breast irradiation for early breast cancer : beware of one-stop shops? Strahlenther Onkol. 2010 Dec;186(12):651-7. doi: 10.1007/s00066-010-8001-2. PubMed PMID: 21127826.
  • Feyer P, Sautter-Bihl ML, Budach W, Dunst J, Haase W, Harms W, Sedlmayer F, Souchon R, Wenz F, Sauer R. DEGRO Practical Guidelines for palliative radiotherapy of breast cancer patients: brain metastases and leptomeningeal carcinomatosis. Strahlenther Onkol. 2010 Feb;186(2):63-69. doi: 10.1007/s00066-010-2100-y. Epub 2010 Jan 26. PubMed PMID: 20127222.
  • Wenz F, Budach W, Dunst J, Feyer P, Haase W, Harms W, Sautter-Bihl ML, Sedlmayer F, Souchon R, Sauer R; DEGRO Expert Panel Breast Cancer. Accelerated partial-breast irradiation (APBI)--ready for prime time? Strahlenther Onkol. 2009 Oct;185(10):653-5. doi: 10.1007/s00066-009-8002-1. PubMed PMID: 19806329.
  • Sautter-Bihl ML, Souchon R, Budach W, Sedlmayer F, Feyer P, Harms W, Haase W, Dunst J, Wenz F, Sauer R. DEGRO practical guidelines for radiotherapy of breast cancer II. Postmastectomy radiotherapy, irradiation of regional lymphatics, and treatment of locally advanced disease. Strahlenther Onkol. 2008 Jul;184(7):347-53. doi: 10.1007/s00066-008-1901-8. PubMed PMID: 19016032.
  • Sautter-Bihl ML, Budach W, Dunst J, Feyer P, Haase W, Harms W, Sedlmayer F, Souchon R, Wenz F, Sauer R; German Society of Radiation Oncology; German Cancer Society. DEGRO practical guidelines for radiotherapy of breast cancer I: breast-conserving therapy. Strahlenther Onkol. 2007 Dec;183(12):661-6. PubMed PMID: 18040609.
  • Sauer R, Sautter-Bihl ML, Budach W, Feyer P, Harms W, Souchan R, Wollwiener D, Kreienberg R, Wenz F. Accelerated partial breast irradiation: Consensus statement of 3 German Oncology societies. Cancer. 2007 Sep 15;110(6):1187-94. Review. PubMed PMID: 17647249.
  • Eichbaum M, Harms W, Bolz S, Schneeweiss A, Sohn C. Generalized lichen ruber planus-induced by radiotherapy of the breast? Onkologie. 2006 Nov;29(11):521-3.  Epub 2006 Oct 25. PubMed PMID: 17068387.
  • Souchon R, Budach W, Dunst J, Feyer P, Haase W, Harms W, Sautter Bihl ML,Wenz F, Sauer R; DEGRO (German Society of Radiation Oncology). Whole-breastirradiation following breast-conserving surgery of ductal carcinomain situ is indispensable. Update of the 2005 DEGRO (German Society of Radiation Oncology) Guideline on Radiation Therapy for Breast Cancer. Strahlenther Onkol. 2006
    Aug;182(8):429-30. German. PubMed PMID: 16896587.
  • Harms W, Krempien R, Grehn C, Hensley F, Berns C, Wannenmacher M, Debus J. Reirradiation of chest wall local recurrences from breast cancer. Zentralbl Gynakol. 2004 Feb;126(1):19-23. Review. German. PubMed PMID: 14981565.
  • Harms W, Krempien R, Hensley FW, Berns C, Fritz P, Wannenmacher M. 5-year results of pulsed dose rate brachytherapy applied as a boost after breast-conserving therapy in patients at high risk for local recurrence from breast cancer. Strahlenther Onkol. 2002 Nov;178(11):607-14. PubMed PMID: 12426671.
  • Thilmann C, Zabel A, Nill S, Rhein B, Hoess A, Haering P, Milke-Zabel S, Harms W, Schlegel W, Wannenmacher M, Debus J. Intensity-modulated radiotherapy of the female breast. Med Dosim. 2002 Summer;27(2):79-90. Review. PubMed PMID: 12074472.
  • Harms W, Krempien R, Hensley FW, Berns C, Wannenmacher M, Fritz P. Results of chest wall reirradiation using pulsed-dose-rate (PDR) brachytherapy molds for breast cancer local recurrences. Int J Radiat Oncol Biol Phys. 2001 Jan 1;49(1):205-10. PubMed PMID: 11163516.
  • Fritz P, Hensley FW, Berns C, Harms W, Wannenmacher M. Long-term results of pulsed irradiation of skin metastases from breast cancer. Effectiveness and sequelae. Strahlenther Onkol. 2000 Aug;176(8):368-76. PubMed PMID: 10987020.

Kontakt Brustzentrum

Claraspital Brustzentrum
Tel.: +41 61 685 89 09
Mo bis Fr 08.00 - 17.00 Uhr
brustzentrum@claraspital.ch

Kontakte für Zuweiser

Kontakt Breast Care Nurse

Alice Jenoure, Breast Care Nurse
Tel.: 061 658 88 24
BreastCare.Nurse@claraspital.ch

Kontakt Claraspital

claraspital.ch
Unsere Telefonzeiten sind Montag bis Freitag von 08.00 - 17.00 Uhr. Ausserhalb der Telefonzeiten ist die Rezeption rund um die Uhr besetzt.

Rezeption:
T: 061 685 85 85